Peptide Research Database

Access 7,487 peer-reviewed studies, clinical trials, and research papers on peptides. Filter by key research, study type, compound, and category. Direct links to full PubMed entries for comprehensive, evidence-based exploration.

Animal Study
Notable
PMID: 42994993
2026 Nov 06

AgRP neurons as an integrative node linking the somatotropic and reproductive axes.

In a mouse study, our results further demonstrate that GH-induced infertility occurs independently of canonical kisspeptin-GnRH dysfunction, revealing a sexually dimorphic mechanism linking somatotropic signaling to reproductive competence.Significance Statement Reproductive dysfunction is a common consequence of long-term alterations in growth hormone (GH) secretion, but the underlying neural mechanisms remain.

Alves GA, Vieira HR, de Sousa LMM, List EO, Kopchick JJ, Sousa LMV, Silva JF, Donato J, Frazao R

Growth hormone (GH) signaling contributes to pubertal development and reproductive function, yet the hypothalamic circuits mediating these effects remain incompletely understood. Kisspeptin and agouti-related protein (AgRP) neurons are key integrators of metabolic and reproductive cues and exhibit GH-responsive signaling pathways. We therefore investigated their contributions to the reproductive consequences of altered somatotropic signaling. Using genetic mouse models of chronic GH excess or deficiency, we examined the impact of altered GH signaling on pubertal maturation, fertility, and hypothalamic neuroendocrine function. Pubertal onset was unaffected in female mice, whereas males with either GH excess or GH deficiency exhibited delayed puberty. In contrast, GH hypersecretion selectively disrupted estrous cyclicity and impaired fertility in females. Female reproductive dysfunction occurred despite preserved kisspeptin signaling, as evidenced by the preservation of intrinsic electrophysiological properties of kisspeptin neurons and unaltered hypothalamic Kiss1 mRNA expression. Chronic GH excess increased hypothalamic Agrp mRNA expression and reduced Pomc and Tac2 mRNA expression compared to control mice; these transcriptional changes were prevented by AgRP-specific GH receptor (GHR) deletion, which also improved ovarian function. Notably, selective deletion of the GHR in AgRP cells markedly improved fertility in GH-hypersecreting females. Together, these findings identify AgRP neurons as a critical hypothalamic target through which chronic GH excess impairs female reproductive function. Our results further demonstrate that GH-induced infertility occurs independently of canonical kisspeptin-GnRH dysfunction, revealing a sexually dimorphic mechanism linking somatotropic signaling to reproductive competence.Significance Statement Reproductive dysfunction is a common consequence of chronic alterations in growth hormone (GH) secretion, but the underlying neural mechanisms remain poorly defined. We show that chronic GH excess induces a sexually dimorphic reproductive phenotype characterized by profound impairment of female fertility despite largely preserved kisspeptin neuronal function. In contrast, GH excess altered hypothalamic AgRP-associated pathways, and the selective deletion of GH receptors in AgRP neurons significantly improved fertility in GH-hypersecreting females. These findings identify AgRP neurons as key mediators of GH-induced reproductive dysfunction and reveal a previously unrecognized sexually dimorphic neuroendocrine mechanism linking somatotropic signaling, metabolic circuits, and female fertility.

The Journal of neuroscience : the official journal of the Society for Neuroscience
Animal Study
Notable
PMID: 42988297
2026 Nov 05

Paternal zearalenone exposure impairs transgenerational male spermatogenesis via the METTL14-m6A-Thap1-glutathione axis.

In a mouse study, paternal exposure to zearalenone, a common mycotoxin in food, impaired sperm production in offspring through altered gene expression patterns that reduced glutathione synthesis. The effect was transmissible across two generations and could be reversed by restoring a single target gene.

Chen C, Ren YT, Lin S, Hu XY, Wei YN, Liu JR, Wang R, Chen YH

Zearalenone (ZEA), a widespread mycotoxin with endocrine-disrupting activity, poses a potential risk to male reproduction. However, the transgenerational effects of paternal ZEA exposure on offspring spermatogenesis and the underlying epitranscriptomic mechanisms remain poorly understood. Here, we investigated whether paternal ZEA exposure causes transgenerational male reproductive toxicity and elucidated the associated epitranscriptomic mechanism. In mice, chronic paternal ZEA exposure (5 mg/kg/day for 10 weeks) significantly reduced sperm count and motility, increased the sperm malformation rate, and disrupted testicular histomorphology in F1 and F2 male offspring. Mechanistically, multi-omics analysis revealed a marked reduction in testicular GSH levels. This reduction was attributable to decreased expression of GSS, the terminal enzyme catalyzing the final step of de novo GSH synthesis, and of GGT7, a GSH hydrolase involved in GSH degradation/recycling; both enzymes are transcriptionally activated by THAP1. Notably, paternal ZEA exposure is associated with increased METTL14-mediated m6A enrichment at candidate sites of Thap1 mRNA, which may promote YTHDF2-dependent decay and reduce THAP1 protein. Knockdown of Mettl14 in paternal testes or targeted overexpression of Thap1 in offspring testes rescued GSH levels, restored spermatogenesis, and alleviated reproductive impairment. Collectively, our findings identify a previously unrecognized epitranscriptional mechanism by which paternal ZEA exposure transmits reproductive toxicity across generations via the METTL14-m6A-Thap1-GSH axis, providing a potential target for intervention against mycotoxin-induced male infertility.

Environmental research
Other
PMID: 42986288
2026 Nov 05

Effectiveness of 25 µg vaginal misoprostol for labor induction in women with obesity: outcomes according to obesity class.

This study found prior vaginal delivery was notably associated with a higher likelihood of vaginal birth. The aim of this study is to evaluate the effectiveness of 25 µg vaginal misoprostol for labor induction in pregnant women with obesity.

Mocarzel CC, Araujo Júnior E, Brito VM, Milagres NM, Oliveira HS, Lattanzi LV, Gomes TS, Callado GY, Moreira DE Sá RA

The aim of this study is to evaluate the effectiveness of 25 µg vaginal misoprostol for labor induction in pregnant women with obesity. This observational analytical study was conducted with a total of 116 pregnant women with singleton gestation, Body Mass Index (BMI) ≥30 kg/m2 at the beginning of prenatal care, and gestational age ≥37 weeks who underwent labor induction with 25 µg vaginal misoprostol were included. Participants were stratified according to obesity class as class I (N.=18), class II (N.=16), and class III (N.=82). The primary outcome was vaginal delivery. Multivariable logistic regression analysis was performed to evaluate the association between obesity class and vaginal delivery, adjusting for maternal age, gestational age, neonatal birthweight, and prior vaginal delivery. Secondary analyses included oxytocin use, duration of labor induction, and neonatal Apgar scores according to obesity class. Obesity class was not significantly associated with vaginal delivery after adjustment for covariates. The adjusted odds ratios were 0.89 for class I versus class II (95% CI 0.19-4.15; P=0.887), 0.95 for class III versus class II (95% CI 0.28-3.16; P=0.952), and 0.94 for class I versus class III (95% CI 0.29-2.97; P=0.916). The mean maternal age was 29.0±5.5 years, and the mean BMI was 49.4±9.4 kg/m2. Chronic hypertension was present in 53.4% of participants, and 36.2% had gestational diabetes mellitus. The mean duration of labor induction was 34.3±17.6 hours. Cesarean delivery occurred in 58.6% of cases, whereas 41.4% achieved vaginal delivery. Baseline maternal, obstetric, and clinical characteristics were similar across obesity classes, except for chronic hypertension with superimposed preeclampsia, which was more frequent in class II (31.3%) compared with class I (16.7%) and class III (8.5%) (P=0.035). Among women who achieved vaginal delivery, oxytocin use and induction duration did not differ significantly across obesity classes. Prior vaginal delivery was significantly associated with mode of delivery in the current pregnancy (χ2<inf>(1)</inf>=11.6; P<0.001), with a higher likelihood of vaginal delivery among women with a history of vaginal birth. In this cohort of pregnant women with obesity, labor induction with 25 µg vaginal misoprostol was effective, and increasing obesity class was not associated with lower vaginal delivery rates. Prior vaginal delivery was significantly associated with a higher likelihood of vaginal birth.

Minerva obstetrics and gynecology
Other
PMID: 42986222
2026 Nov 05

Association Between Early Postpartum Maternal Fatigue and Infant Emotional Development: Protocol for a Prospective Cohort Study.

This study found the findings may help identify high-risk mother-infant subgroups and provide real-world evidence to develop targeted early screening and dyadic support strategies for postpartum mothers and their infants.

Xu Z, Ni J, Wei R, Zhang F

Postpartum fatigue (PPF) is clinically defined as persistent physical and mental exhaustion emerging after childbirth that cannot be fully relieved by rest. It is distinct from postpartum depression and has a prevalence of 76.13% among Chinese women within the first postpartum week. Existing evidence suggests that maternal PPF may alter salivary oxytocin concentrations, disturb maternal caregiving behaviors, and subsequently interfere with multiple dimensions of infant emotional development, including emotional expression, emotional regulation, and emotional recognition. Objective psychophysiological measurements, such as eye-tracking and galvanic skin response, have been validated for assessing infant emotional responses. Nevertheless, most existing studies focus merely on maternal mental well-being. Local longitudinal evidence clarifying this sequential mechanistic chain remains limited, and targeted early screening and intervention strategies for PPF-affected mother-infant dyads are insufficient. This prospective cohort protocol aims to examine the independent association between maternal PPF and the emotional development of 3-month-old infants and to explore the sequential mediating roles of salivary oxytocin and mother-infant caregiving quality. The primary hypothesis is that higher PPF severity will correlate with poorer infant emotional development outcomes. The secondary hypothesis is that oxytocin levels and maternal caregiving sequentially mediate this association. We will recruit 412 mother-infant dyads with maternal PPF within 1 week postpartum. PPF severity will be measured by the Postpartum Fatigue Scale. Infant emotional development, covering expression, regulation, and recognition, will be evaluated via questionnaires and physiological assessments, including eye-tracking and galvanic skin response, at an infant age of 3 months. General analytical frameworks will be applied for hypothesis testing. This study was funded and initiated in September 2025. Participant recruitment commenced in October 2025. A total of 180 mothers-infants dyads underwent eligibility screening; 146 of these dyads completed enrollment, yielding a participation rate of 81.1%. Twelve dyads withdrew before the 3-month follow-up window, and 4 dyads were lost to follow-up at the 3-month assessment. To date, 112 dyads have completed the full 3-month postpartum assessment, and the remaining participants are still under follow-up. No major protocol deviations have occurred. Data analysis of samples from participants who have completed the 3-month assessments is ongoing. According to the prespecified timeline, full sample collection is projected to be completed by December 2027, and formal data analysis will begin shortly thereafter. The study is progressing steadily in accordance with preset schedules. Full dataset analysis and submission of the final manuscript are anticipated in early 2028. This cohort will generate longitudinal evidence describing links between maternal PPF and early infant emotional development in Chinese postpartum populations. The findings may help identify high-risk mother-infant subgroups and provide real-world evidence to develop targeted early screening and dyadic support strategies for postpartum mothers and their infants.

JMIR research protocols
Other
PMID: 42987410
2026 Nov 05

Statement of Retraction: The protective effects of S14G-humanin (HNG) against mono-sodium urate (MSU) crystals- induced gouty arthritis.

Bioengineered
Other
PMID: 42989432
2026 Nov 05

Oxytocin discontinuation and fetal heart rate: Physiological effect, fetal rotation, or regression to the mean?

Mappa I, Rizzo G

Acta obstetricia et gynecologica Scandinavica
Clinical Trial
Highly Cited
PMID: 42988221
2026 Nov 05

Semaglutide versus diet-based weight loss in obesity and heart failure with reduced ejection fraction (FIT-HF): Protocol for a randomized controlled trial.

In a randomized trial, FIT-HF is the first direct comparison of these weight-loss strategies in obesity and HFrEF, integrating VO2peak with multimodal phenotyping to interpret physiological profiles alongside achieved weight loss and body composition.

El-Sheikh M, Bandholm T, Jørgensen NB, Ulrik CS, Barløse M, Møller S, Siebner HR, Grand J, Barasa A, Petersen M, Madsbad S, Yang Lee MM, Dirksen C, Hove JD

Obesity is common in heart failure with reduced ejection fraction (HFrEF), but the functional, mechanistic, and safety consequences of intentional weight loss remain uncertain. Incretin-based therapies improve symptoms and functional capacity in obesity-related heart failure with preserved ejection fraction, whereas evidence in HFrEF is limited, and prior glucagon-like peptide-1 receptor agonist trials have raised safety concerns. The FIT-HF trial tests whether semaglutide-based weight loss is superior to intensive diet-based weight loss for improving exercise capacity in adults with obesity and stable HFrEF. FIT-HF is an investigator-initiated, randomized, parallel-group, open-label, assessor-blinded, active-comparator superiority trial enrolling 100 adults with body mass index ≥30 kg/m2, left ventricular ejection fraction ≤40%, New York Heart Association class I-III symptoms, and stable guideline-directed heart failure therapy. Participants are randomized 1:1 to once-weekly subcutaneous semaglutide, titrated to a target dose of 2.4 mg, or low-calorie total dietary replacement of approximately 800 kcal/day for 8 weeks followed by a dietitian-led weight-maintenance program. Both groups receive lifestyle counseling, heart failure care, and structured physical training from week 16. Follow-up is 52 weeks. The primary endpoint is the adjusted between-group difference in change in weight-indexed peak oxygen uptake (VO2peak) from baseline to week 52, assessed by cardiopulmonary exercise testing. Supportive secondary endpoints include Kansas City Cardiomyopathy Questionnaire score, 6-min walk distance, left ventricular end-systolic volume assessed by cardiovascular magnetic resonance, high-sensitivity C-reactive protein, and N-terminal pro-B-type natriuretic peptide. Exploratory work packages assess safety, cardiac/pulmonary physiology, body composition, physical activity, and metabolic/biomarker responses. FIT-HF is the first direct comparison of these weight-loss strategies in obesity and HFrEF, integrating VO2peak with multimodal phenotyping to interpret physiological profiles alongside achieved weight loss and body composition. European Clinical Trials Information System: European Union trial number: CT-2023-503753-35-01; ClinicalTrials.gov identifier: NCT06423599.

Clinical nutrition ESPEN
Animal Study
DOI
2026-11-05

Sex differences in cell type-specific transcriptional programs and GPCR signaling in the human subgenual anterior cingulate cortex

In a mouse study, collectively, our findings demonstrate cell type-specific sex differences in the sgACC corresponding to functional differences in neuromodulator signaling, with potential implications for treatment response. Here, we examined molecularly distinct cell types within the subgenual anterior cingulate cortex (sgACC) of non-psychiatric subjects.

Snowden AW, Li NY, Sibille E, Joffe ME, Seney ML.

Psychiatric conditions show marked sex differences in disease onset, symptom presentation, and response to treatments. Understanding how sex differences manifest across molecularly distinct neuronal populations in individuals without psychiatric conditions may help explain sex-dependent variation in neural circuit function and treatment response. Here, we examined molecularly distinct cell types within the subgenual anterior cingulate cortex (sgACC) of non-psychiatric subjects. Using RNA sequencing data previously generated from laser-capture microdissected neurons, we investigated sex differences in gene expression and co-expression networks in excitatory pyramidal neurons (layers 2/3 and 5/6) and somatostatin (SST)-, parvalbumin (PVALB)-, and vasoactive intestinal peptide (VIP)-expressing inhibitory interneurons (N=10 males, 9 females). We identified sex differences in transcriptomic profiles, biological pathways, and co-expression network connectivity. PVALB cells showed stronger overall female transcriptional enrichment, while SST cells exhibited male-enriched transcriptional signatures. Weighted gene co-expression network analysis identified PVALB and SST modules more connected in males and females, respectively, which included hub genes involved in immune, extracellular matrix, and bioenergetic processes. Since G protein-coupled receptors (GPCRs) are viable therapeutic targets, we examined sex differences in GPCR transcripts. Across all GPCR-cell-type combinations, CHRM2 in PVALB cells showed the second strongest sex difference (enriched in females). To test the functional relevance of this difference, we used patch-clamp electrophysiology in mouse prefrontal cortex. M2 receptor activation increased maximal firing rates in PVALB cells from female but not male mice. Collectively, our findings demonstrate cell type-specific sex differences in the sgACC corresponding to functional differences in neuromodulator signaling, with potential implications for treatment response.

Meta-Analysis
Landmark Study
PMID: 42987980
2026 Nov 05

The effect of subcutaneous semaglutide injection on blood pressure: a systematic review and meta-analysis of randomized controlled trials.

In a combined analysis of multiple studies, blood pressure improvement represents one component of semaglutide's cardiometabolic benefits.

Ahmadi N, Zandi R, Norouzi M, Prabahar K, Kashi A, Basiri A, Varkaneh HK

Hypertension remains a leading contributor to cardiovascular disease globally. Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), reduces blood pressure in clinical trials, but the consistency and magnitude of this effect across populations is unclear. We conducted a systematic review and meta-analysis of placebo-controlled randomized trials reporting blood pressure changes in patients receiving subcutaneous semaglutide. MEDLINE, Web of Science, and Embase were searched through December 2025. Pooled weighted mean differences with 95% confidence intervals were calculated using random-effects inverse-variance models. Cochrane's RoB 2.0 assessed risk of bias, and the Grading of recommendations Assessment Development and Evaluation (GRADE) approach was used to evaluate the certainty of the evidence. Our meta-analysis included seven trials with approximately 20,000 patients. Semaglutide reduced systolic blood pressure (SBP) significantly compared with placebo across 11 arms (20,011 participants): weighted mean difference -3.46 mmHg (95% CI: -4.44 to -2.49; I2 = 29.5%; high certainty of evidence). A modest reduction in diastolic blood pressure (DBP) was also observed (-0.56 mmHg, 95% CI: -0.82 to -0.29; I2 = 0.0%; moderate certainty of evidence). However, sensitivity analysis revealed that the DBP effect was dependent on a single large study, with loss of significance upon its exclusion. Subcutaneous semaglutide produces meaningful SBP reduction across diverse patient populations, with minimal DBP changes. Blood pressure improvement represents one component of semaglutide's cardiometabolic benefits.

Diabetes research and clinical practice
Animal Study
Notable
PMID: 42988012
2026 Nov 05

Oxytocin receptor activation enhances SK channel-mediated afterhyperpolarization in MPOA neurons of maternally experienced mice.

In a mouse study, these findings suggest that oxytocin modulates SK channel activity to reduce the excitability of a subpopulation of MPOA brain cells.

Ma G, Yang X, Huang Q, Li J, Mao H, Xue Q, Hu E, Wu S, Qi C, Wang W

Maternal experience induces significant behavioral changes; however, the underlying cellular mechanisms within the medial preoptic area (MPOA), a central hub for regulating maternal behavior, remain poorly understood. Here, we combined behavioral assays (e.g., pup retrieval, crouching, nesting, and grooming) with in vitro whole-cell patch-clamp recordings to examine how maternal experience alters the intrinsic excitability of MPOA neurons and to identify the underlying mechanisms. Adult female mice were divided into three groups: virgin females, dams (experienced dams), and co-housed virgins (virgins co-housed with a dam and her pups for five days). Maternal behavior and the intrinsic properties of MPOA neurons were assessed in all three groups. We first compared virgin females with experienced dams, and then tested whether the maternal experience-dependent changes in MPOA neurons were reproduced in co-housed virgins by social co-housing. Our results revealed that MPOA neurons from both dams and co-housed virgins exhibited reduced excitability and increased afterhyperpolarization (AHP) amplitude. This enhancement was mediated by small-conductance calcium-activated potassium (SK) channels, as it was abolished by the SK channel blocker apamin. Furthermore, direct application of an oxytocin receptor agonist to MPOA neurons from virgin females induced similar functional changes, replicating the physiological profile observed in dams. Notably, this oxytocin-induced enhancement of SK channel activity was observed in glutamatergic, but not GABAergic, MPOA neurons, indicating that the effect is not uniform across cell types. These findings suggest that oxytocin modulates SK channel activity to reduce the excitability of a subpopulation of MPOA neurons. Because this effect was prominent in VGLUT2-positive neurons, it may facilitate maternal behavior by reducing the activity of neurons that restrain maternal behavior, a candidate mechanism by which hormonal and experiential signals converge on MPOA excitability.

Brain research bulletin